Science and health must drive decisions on abortion access

Apr 14, 2023

Recent federal court rulings to restrict use of FDA-approved drug mifepristone are inconsistent with evidence on safety and efficacy

Recent decisions regarding approval of the FDA-approved drug mifepristone contradicts over 100 peer-reviewed studies. The drug has been used to safely and effectively induce abortion  and treat miscarriages among over five million Americans. There is no scientific basis for denying access. 

As an institution whose work centers around scholarship and science for social change, we do not support decisions to restrict access to mifepristone or abortion. Our work has global reach, and we fear for the health and well-being of pregnant people in countries that have outlawed and restricted access to abortion, including the United States. We remain committed to supporting reproductive health and rights worldwide for all.

About Gates Institute

Located in the Department of Population, Family and Reproductive Health at the Johns Hopkins Bloomberg School of Public Health, the Gates Institute is dedicated to the advancement of scholarship and science for social change. The Institute conducts and facilitates cutting-edge research in family planning, adolescent and youth reproductive health and population dynamics, and translates science into evidence-informed policies, programs and practice.

For more information, please visit www.gatesinstitute.org.

Read Gates Institute’s statement on the 2022 US Supreme Court decision to overrule 50 years of precedent for abortion rights.

 

Related Content

 

Kwame Nkrumah University in Ghana Receives Funding to Facilitate Strategic Leadership Training for Health Systems Transformation

Kwame Nkrumah University in Ghana Receives Funding to Facilitate Strategic Leadership Training for Health Systems Transformation

Gates Institute Director Jose ‘Oying’ Rimon to Retire after Distinguished Career Championing Global Health Causes Such as Family Planning and Reproductive Health

Gates Institute Director Jose ‘Oying’ Rimon to Retire after Distinguished Career Championing Global Health Causes Such as Family Planning and Reproductive Health

William H. Gates Sr. Institute for Population and Reproductive Health Unveils Refreshed Strategy through 2030

William H. Gates Sr. Institute for Population and Reproductive Health Unveils Refreshed Strategy through 2030

Bloomberg School Honors William H. Gates Sr. with New Name for Gates Institute for Population and Reproductive Health 

Bloomberg School Honors William H. Gates Sr. with New Name for Gates Institute for Population and Reproductive Health 

Innovate, Inspire, Impact. The Legacy Continues.

Innovate, Inspire, Impact. The Legacy Continues.

World Contraception Day 2023 Recap from Gates Institute

World Contraception Day 2023 Recap from Gates Institute

Using Family Planning To Achieve Universal Health Coverage

Using Family Planning To Achieve Universal Health Coverage

How a Vast Demographic Shift Will Reshape  the World: Gates Institute Demographic Dividend Initiative Member Quoted

How a Vast Demographic Shift Will Reshape the World: Gates Institute Demographic Dividend Initiative Member Quoted

Let Youth Lead: The Global Roadmap for Action in Adolescent Sexual and Reproductive Health

Let Youth Lead: The Global Roadmap for Action in Adolescent Sexual and Reproductive Health

WATCH: Demographic Dividend Webinar on Generational Economy

WATCH: Demographic Dividend Webinar on Generational Economy